CDDW Abstracts 2008
Return to Main Menu
Search CDDW 2008 Abstracts
POSTER SESSION II - VIRAL HEPATITIS
223 - VARIATION IN RESPONSE TO PEGYLATED INTERFERON AND RIBAVIRIN THERAPY BETWEEN DIFFERENT GENOTYPES...
224 - GIANT CELL HEPATITIS IN BRITISH COLUMBIA: THE EXPERIENCE IN A TERTIARY HEPATOLOGY AND LIVER TRA...
225 - ON-DEMAND LOW-DOSE HEPATITIS B IMMUNOGLOBULIN WITH ANTIVIRAL THERAPY IS EFFECTIVE PROPHYLAXIS P...
226 - PERIPHERAL BLOOD DENDRITIC CELL SUBSETS AND SERUM INTERLEUKIN-12 LEVELS IN PATIENTS WITH CHRONI...
227 - WHO GET LAMIVUDINE RESISTANCE AND HOW CAN WE OPTIMIZE THE TREATMENT IN PATIENTS WITH CHRONIC VI...
228 - ASSOCIATION BETWEEN BMI AND HEPATITIS C IN THE UNITED STATES
229 - EVALUATION OF TETRAHYDROCANNABINOL-CONTAINING ORAL MEDICATIONS FOR HEPATITIS C VIRUS ANTIVIRAL ...
230 - FUNCTIONAL PROTEOMICS: HUMAN CARBOXYLESTERASE I PROMOTES HEPATITIS C REPLICATION
231 - HCV RNA MICROARRAYS: AN IN VITRO APPROACH TO SCREEN FOR HIGH AFFINITY SIRNA INTERACTIONS WITH T...
232 - HEALTH OUTCOMES IN PATIENTS WITH CHRONIC HEPATITIS C TREATED IN COMMUNITY VERSUS ACADEMIC CENTR...
233 - SPONTANEOUS CLEARANCE OF HEPATITIS C POST LIVER AND KIDNEY TRANSPLANT
234 - A SYSTEMATIC REVIEW OF THE EFFECTIVENESS OF PEGYLATED INTERFERON, LAMIVUDINE, ADEFOVIR AND ENTE...
235 - REINFECTION FOLLOWING SUCCESSFUL TREATMENT FOR HEPATITIS C VIRUS INFECTION WITH EITHER INTERFER...
236 - INFLUENCE OF IMMIGRATION STATUS ON CHRONIC HEPATITIS C VIRUS INFECTION MANAGEMENT
237 - LOW RATE OF HEPATITIS C VIRUS (HCV) RE-INFECTION AMONG INJECTION DRUG USERS (IDUS) FOLLOWING SU...
238 - TREATMENT UPTAKE AND OUTCOMES AMONG INJECTION DRUG USERS (IDUS) IN A MULTIDISCIPLINARY PROGRAM ...
239 - EXTREMELY LOW UPTAKE OF HEPATITIS C VIRUS (HCV) INFECTION TREATMENT IN A COMMUNITY-BASED STUDY ...
240 - MONITORING CHANGES IN LIPID METABOLISM IN LIVING HUMAN HEPATOMA CELLS EXPRESSING HCV CORE USING...
241 - HEPATITIS C CARE IN A COMMUNITY BASED LOW THRESHOLD METHADONE PROGRAM: INITIAL EXPERIENCE
242 - HEPATITIS B IN HIV-INFECTED PATIENTS VACCINATED FOR HBV
243 - SURVEILLANCE FOR HEPATITIS B VIRUS (HBV) ANTIVIRAL RESISTANCE (AVR) IN CLINICAL PRACTICE: WHAT ...
244 - APPLYING META-ANALYSIS TO MICROARRAY: IDENTIFICATION OF A ROBUST GENE SIGNATURE FOR CHRONIC HCV
245 - INVOLVEMENT OF AKT IN THE UP-REGULATION OF FATTY ACID SYNTHASE PROMOTER BY HCV-3A CORE PROTEIN
246 - PREVALENCE AND PREDICTORS OF OBESITY AMONG INDIVIDUALS WITH POSITIVE HEPATITIS C ANTIBODY IN A ...
247 - TREATENT OUTCOMES OF HEPATITIS C INFECTED PATINETS WITH DIFFERENT AMINOTRANSFERASE (ALT) LEVELS
248 - IMPROVING ACCESS TO CARE BY ALLOWING SELF REFERRAL TO A HEPATITIS C CLINIC
249 - COST-EFFECTIVENESS OF ADDING IN ADEFOVIR FOLLOWING CLINICAL OR VIROLOGIC RESISTANCE TO LAMIVUDI...
250 - HCV TREATMENT RESPONSE IN HIV/HCV CO-INFECTED PATIENTS: RELATIONSHIP TO BASELINE CD4 COUNT
251 - IMMUNE CORRELATES OF TREATMENT INDUCED DEPRESSION IN CHRONIC HCV INFECTION
252 - BMI AND WEIGHT ARE NOT PREDICTORS OF RESPONSE TO ANTIVIRAL TREATMENT IN CHRONIC HEPATITIS C (HC...
253 - DOES THERAPEUTIC TOUCH EASE FATIGUE AND DEPRESSION IN PATIENTS UNDERGOING HEPATITIS C THERAPY W...
254 - RESPONSE TO PEGINTERFERON alpha-2B + RIBAVIRIN COMBINATION THERAPY IN HIV-HCV CO-INFECTED PATIE...
255 - PREDICTORS OF RELAPSE IN THE CANADIAN POWER (PEGETRON PROSPECTIVE OPTIMAL WEIGHT-BASED DOSING R...
256 - IMPACT OF FIBROSIS AND VIRAL LOAD ON SUSTAINED VIROLOGIC RESPONSE OF G2 AND G3 PATIENTS TREATED...
257 - RETROSPECTIVE COMPARISON OF STANDARD VERSUS PEGYLATED (PEG) INTERFERON (IFN) ALPHA-2B IN CHINES...